FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Mathur, Anjili ^a   Ware, Christopher ^a   Davis, Lenora ^a   Gazdar, Adi ^b   Pan, Bo Sheng ^a   Lutterbach, Bart ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MK 2461; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN KINASE B; PROTEIN S6; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; FGFR2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FGFR2 GENE; GENE ACTIVATION; GENE AMPLIFICATION; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALIGNANT ASCITES; MOUSE; NCI H716 CELL LINE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL SURVIVAL; COLORECTAL TUMOR; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; GENE AMPLIFICATION; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903388651     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098515     Document Type: Article

References (33)

1. O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425.
2. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
3. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. (Pubitemid 38541907)
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
5. Untawale S, Zorbas MA, Hodgson CP, Coffey RJ, Gallick GE, et al. (1993) Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene. Cancer Res 53: 1630-1636. (Pubitemid 23113243)
6. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, et al. (2004) Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 17: 895-904. (Pubitemid 38993773)
7. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101: 1308-1324.
8. Pavlakis K, Kountourakis P, Stathopoulos E, Psyrri A, Rontogianni D, et al. (2007) Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma. Appl Immunohistochem Mol Morphol 15: 441-445. (Pubitemid 350307851)
9. Sorscher SM (2011) Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest 29: 456-459.
10. Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH (2012) Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 43: 1559-1566.
11. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, et al. (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013-2023.
12. Heiskanen M, Kononen J, Barlund M, Torhorst J, Sauter G, et al. (2001) CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal Cell Pathol 22: 229-234. (Pubitemid 32960014)
13. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, et al. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 70: 1524-1533.
14. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, et al. (2008) FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 68: 2340-2348. (Pubitemid 351521808)
15. Moffa AB, Tannheimer SL, Ethier SP (2004) Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2: 643-652. (Pubitemid 39557667)
16. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, et al. (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2: 1373-1381. (Pubitemid 26299437)
17. Yoshida T, Sakamoto H, Terada M (1993) Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 4: 33-40.
18. Katz JD, Jewell JP, Guerin DJ, Lim J, Dinsmore CJ, et al. (2011) Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer. J Med Chem 54: 4092-4108.
19. Parada LA, McQueen PG, Munson PJ, Misteli T (2002) Conservation of relative chromosome positioning in normal and cancer cells. Curr Biol 12: 1692-1697. (Pubitemid 35161925)
20. Klokk TI, Kurys P, Elbi C, Nagaich AK, Hendarwanto A, et al. (2007) Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol 27: 1823-1843.
21. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, et al. (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67: 2081-2088. (Pubitemid 46424226)
22. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. (Pubitemid 46799492)
23. Sekiguchi M, Sakakibara K, Fujii G (1978) Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn J Exp Med 48: 61-68. (Pubitemid 8328492)
24. Dahlberg PS, Jacobson BA, Dahal G, Fink JM, Kratzke RA, et al. (2004) ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg 78: 1790-1800. (Pubitemid 39423556)
25. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6. (Pubitemid 38391943)
26. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362. (Pubitemid 43128863)
27. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, et al. (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177: 415-423.
28. de Bruine AP, Dinjens WN, Pijls MM, vd Linden EP, Rousch MJ, et al. (1992) NCI-H716 cells as a model for endocrine differentiation in colorectal cancer. Virchows Arch B Cell Pathol Incl Mol Pathol 62: 311-320.
29. Park JG, Oie HK, Sugarbaker PH, Henslee JG, Chen TR, et al. (1987) Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 47: 6710-6718. (Pubitemid 18019675)
30. Zbuk K, Sidebotham EL, Bleyer A, La Quaglia MP (2009) Colorectal cancer in young adults. Semin Oncol 36: 439-450.
31. Tanoue Y, Tanaka N, Suzuki Y, Hata S, Yokota A (2009) A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism. World J Gastroenterol 15: 248-251.
32. Itoh H, Hattori Y, Sakamoto H, Ishii H, Kishi T, et al. (1994) Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Res 54: 3237-3241. (Pubitemid 24208935)
33. Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, et al. (2012) FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2: 1118-1133.